Revance Therapeutics Inc (RVNC) Drug-Induced High Rewards Call Buyers

Revance Therapeutics Inc (RVNC) hit an annual high earlier on upbeat drug trial results

by Alex Eppstein

Published on Oct 29, 2015 at 11:30 AM

Revance Therapeutics Inc (NASDAQ:RVNC) announced earlier that its anti-wrinkle drug showed promise in a mid-stage study, and said it expects to launch a late-stage trial in the second half of 2016. Wall Street is reacting positively, as evidenced by the stock's nearly 30% midday jump to trade at $34.58. In fact, the shares have now more than doubled in 2015, and earlier topped out at an annual high of $36.89.

This is good news for recent call buyers. RVNC has racked up a call/put volume ratio of 2.33 during the last 10 weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). In other words, traders have bought to open more than twice as many calls as puts in recent months. Today, though, puts are crossing at 12 times the usual intraday rate, and outstripping calls by a slight margin.

Sentiment is upbeat among analysts, too, as all three firms tracking RVNC have doled out "strong buy" recommendations. Moreover, short sellers have been quickly unwinding their bearish bets, with short interest dropping by one-quarter during the latest reporting period. However, 9% of the equity's float remains dedicated to short interest, and would require 7.5 sessions to cover, at typical volumes. In other words, a continued unwinding of these positions could fuel further upside in Revance Therapeutics Inc (NASDAQ:RVNC) shares.

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Wall Street Roars Higher Amid Civil Unrest
Investors weighed a mixed bag of jobs data
AstraZeneca Stock Flat Despite COVID-19 Vaccine News
AstraZeneca saw a rise in capacity for its COVID-19 vaccine candidate
The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.